Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Ionis Pharmaceuticals Inc’s stock clocked out at $73.07, up 0.94% from its previous closing price of $72.39. In other words, the price has increased by $0.94 from its previous closing price. On the day, 1.71 million shares were traded. IONS stock price reached its highest trading level at $74.42 during the session, while it also had its lowest trading level at $72.07.
Ratios:
To gain a deeper understanding of IONS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 16 ’25 when Swayze Eric sold 53 shares for $73.62 per share. The transaction valued at 3,902 led to the insider holds 256 shares of the business.
PARSHALL B LYNNE sold 5,000 shares of IONS for $358,722 on Oct 15 ’25. The Director now owns 61,344 shares after completing the transaction at $71.74 per share. On Oct 15 ’25, another insider, Devers Shannon L., who serves as the EVP, Chief Human Resources Ofc of the company, sold 6,000 shares for $72.94 each. As a result, the insider received 437,654 and left with 15,937 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 11646716928 and an Enterprise Value of 11337750528. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.33 while its Price-to-Book (P/B) ratio in mrq is 18.41. Its current Enterprise Value per Revenue stands at 12.01 whereas that against EBITDA is -44.432.
Stock Price History:
The Beta on a monthly basis for IONS is 0.31, which has changed by 0.8414818 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $73.92, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 27.47%, while the 200-Day Moving Average is calculated to be 82.05%.
Shares Statistics:
It appears that IONS traded 2.46M shares on average per day over the past three months and 2192860 shares per day over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 158.19M. Insiders hold about 0.76% of the company’s shares, while institutions hold 106.88% stake in the company. Shares short for IONS as of 1759190400 were 12278792 with a Short Ratio of 5.00, compared to 1756425600 on 10502338. Therefore, it implies a Short% of Shares Outstanding of 12278792 and a Short% of Float of 10.22.
Earnings Estimates
. The current rating of Ionis Pharmaceuticals Inc (IONS) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.95 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$1.63 and -$2.49 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.96, with 11.0 analysts recommending between -$0.46 and -$3.17.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $131.75M. It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 19 analysts are estimating revenue of $144.84M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.
A total of 24 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $832.78M, resulting in an average revenue estimate of $866.22M. In the same quarter a year ago, actual revenue was $705MBased on 23 analysts’ estimates, the company’s revenue will be $899.23M in the next fiscal year. The high estimate is $1.15B and the low estimate is $681.53M.
